StockNews.AI
JAGX
StockNews.AI
144 days

83.33% of Veterinary Oncologists Highlight Importance of Jaguar Health's FDA Conditionally Approved Canalevia-CA1 as a Non-Antibiotic Treatment for Chemotherapy-Induced Diarrhea (CID) in Dog's in New Survey

1. Jaguar Health's Canalevia-CA1 is the first FDA-approved CID treatment for dogs. 2. Survey of veterinary oncologists highlights unmet need in treating CID during chemotherapy.

2m saved
Insight
Article

FAQ

Why Bullish?

The FDA approval of Canalevia-CA1 positions JAGX strongly in a niche market. Historical sales spikes followed similar announcements in biotech companies, indicating potential for price increases.

How important is it?

The FDA approval directly enhances JAGX's product portfolio, appealing to veterinary markets. This move can bolster investor confidence and market competitiveness.

Why Short Term?

The immediate effect of the FDA approval can drive sales in the near future. Similar cases, such as other veterinary drug approvals, typically see stock impacts within 1-3 months post-announcement.

Related Companies

CHEWYPFEMRK
Canalevia®-CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need SAN FRANCISCO, CA / ACCESS Newswire / March 28, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the veterinary market, today announced the results of a new survey of 27 board certified veterinary oncologists practicing in the U.S. regarding Canalevia-CA1 and the treatment of chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1, the company's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug product for the treatment of CID in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy.

Related News